Applied DNA Sciences, Inc. (APDN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7389 |
| Open | 0.7430 |
| Bid | 0.7100 x 3000 |
| Ask | 0.7350 x 1300 |
| Day's Range | 0.6680 - 0.7590 |
| 52 Week Range | 0.6680 - 8.1000 |
| Volume | |
| Avg. Volume | 87,248 |
| Market Cap | 5.83M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9060 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APDN
Related Research
- Applied DNA Sciences, Inc.Daily – Vickers Top Buyers & Sellers for 03/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- Business Wire
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
STONY BROOK, N.Y., June 29, 2022--Applied DNA expands industry awareness of LinearDNA platform as an alternative to plasmid DNA for therapeutic applications.
- Business Wire
U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act
STONY BROOK, N.Y., June 21, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in cell-free, enzymatic DNA production, has been increasing its engagement with all stakeholders in anticipation of the June 21, 2022, effective date of the "rebuttable presumption" standard under the Uyghur Forced Labor Prevention Act (UFLPA) signed into law on December 23, 2021. Under the UFLPA, all imports that originate from China's Xinjiang Uyghur Autonomous Region (XUAR) or otherwise use U
- Business Wire
Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
STONY BROOK, N.Y. and ROME, Italy, June 06, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform to produce veterinary DNA cancer vaccines. LinearDNA is Applied DNA's proprietary, lar
